Yahoo
Brussels - Delayed Quote EUR

Onward Medical N.V. (ONWD.BR)

2.4600 +0.0050 (+0.20%)
As of 10:59:18 AM GMT+2. Market Open.
Chart Range Bar
Loading chart for ONWD.BR
  • Previous Close 2.4550
  • Open 2.4600
  • Bid --
  • Ask --
  • Day's Range 2.4500 - 2.4900
  • 52 Week Range 2.2700 - 5.7700
  • Volume 17,148
  • Avg. Volume 101,024
  • Market Cap (intraday) 171.04M
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9000
  • Earnings Date Sep 9, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.24

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven movement of the legs and upper extremities. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

www.onwd.com

137

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

ONWD.BR
45.58%
BEL 20 (^BFX)
15.57%

1-Year Return

ONWD.BR
53.85%
BEL 20 (^BFX)
23.67%

3-Year Return

ONWD.BR
45.70%
BEL 20 (^BFX)
60.48%

5-Year Return

ONWD.BR
81.11%
BEL 20 (^BFX)
36.35%

Analyst Insights

View More

Analyst Price Targets

8.10
9.24 Average
2.4600 Current
11.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    169.65M

  • Enterprise Value

    115.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    30.13

  • Price/Book (mrq)

    3.07

  • Enterprise Value/Revenue

    30.48

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.80%

  • Return on Equity (ttm)

    -80.85%

  • Revenue (ttm)

    5.41M

  • Net Income Avi to Common (ttm)

    -41.79M

  • Diluted EPS (ttm)

    -0.9000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    68.11M

  • Total Debt/Equity (mrq)

    24.70%

  • Levered Free Cash Flow (ttm)

    -23.79M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: